Journal: Andrologia

Article Title: NAD(P)H-quinone oxidoreductase 1 silencing aggravates hormone-induced prostatic hyperplasia in mice.

doi: 10.1111/and.12906

Figure Lengend Snippet: FIGURE 4 NAD(P)H-quinone oxidoreductase 1 (NQO1) knockout enhanced nuclear expression of androgen receptor (AR) and proliferating cell nuclear antigen (PCNA) in the prostate tissue of testosterone-treated mice. Both wild-type and NQO1−/− C57BL/6 mice (n = 7 mice/group) were sacrificed after testosterone propionate (3 mg/kg, TCI) injection treatment for 14 consecutive days. The arrow indicates positive-stained nuclei in prostate epithelial cells

Article Snippet: Human prostate adenocarcinoma cells (LNCaP; KCLB, Seoul, Korea), human prostate epithelial cells (BPH- 1; DSMZ, Brunswick, Germany) and human prostate stromal cells (WPMY- 1; ATCC, Manassas, VA, USA) were cultured in RPMI 1640 (LNCaP and BPH- 1) or DMEM (WPMY- 1) medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C in an atmosphere with 5% CO2, with the media being replaced every 48 hr.

Techniques: Knock-Out, Expressing, Injection, Staining

Journal: International Journal of Molecular Sciences

Article Title: Changes in the Expression and Functional Activities of C-X-C Motif Chemokine Ligand 13 ( CXCL13 ) in Hyperplastic Prostate

doi: 10.3390/ijms24010056

Figure Lengend Snippet: The expression of CXCL13 in human serum, prostate tissue and cell lines. ( A ) Serum CXCL13 concentration in BPH patients and healthy controls. ( B , C ) The protein and mRNA expression of CXCL13 in BPH tissues and normal ones. ( D – F ) The mRNA and protein expression of CXCL13 in BPH-1 and WPMY-1 cells. Representative blots are shown. * p < 0.05, ** p < 0.01 and *** p < 0.001. ( G , H ) Immunofluorescence localization of CXCL13 in BPH tissues and normal ones. ( I , J ) Immunofluorescence localization of CXCL13 in BPH-1 and WPMY-1 cells. DAPI (blue) indicates nuclear staining and Cy3-immunofluorescence (red) indicates CXCL13 protein staining. Representative graphs are shown. All scale bars are 100 μm.

Article Snippet: Human benign prostatic enlargement epithelia cell line BPH-1 (Cat. BNCC339850) was purchased from the Procell Co., Ltd. in Wuhan, China.

Techniques: Expressing, Concentration Assay, Immunofluorescence, Staining

Journal: International Journal of Molecular Sciences

Article Title: Changes in the Expression and Functional Activities of C-X-C Motif Chemokine Ligand 13 ( CXCL13 ) in Hyperplastic Prostate

doi: 10.3390/ijms24010056

Figure Lengend Snippet: rHuCXCL13 treatment promoted proliferation of BPH-1 cells, fibrosis and inflammation of WPMY-1 cells. ( A , B ) Flow cytometry analysis of cell cycle and cell apoptosis in BPH-1 cells. ( C , D ) Statistical analysis of percentages (%) of cells at each stage and apoptotic rate (%) in BPH-1 cells. ( E ) CCK8 assay of BPH-1 cells. ( F , G ) Western blot assay of EMT-, cell-cycle- and apoptosis-related proteins in BPH-1 cells. ( H – J ) The mRNA and protein expression of markers of fibrosis and inflammation in WPMY-1 cells. * p < 0.05, ** p < 0.01 and ns means no significant difference.

Article Snippet: Human benign prostatic enlargement epithelia cell line BPH-1 (Cat. BNCC339850) was purchased from the Procell Co., Ltd. in Wuhan, China.

Techniques: Flow Cytometry, CCK-8 Assay, Western Blot, Expressing

Journal: International Journal of Molecular Sciences

Article Title: Changes in the Expression and Functional Activities of C-X-C Motif Chemokine Ligand 13 ( CXCL13 ) in Hyperplastic Prostate

doi: 10.3390/ijms24010056

Figure Lengend Snippet: Knockdown of CXCL13 inhibited proliferation, EMT and promoted apoptosis of BPH-1 cells via ERK1/2 and AKT pathway. ( A – C ) Knockdown efficiency of CXCL13 at mRNA and protein levels. ( D , F ) Statistical analysis of apoptotic rate (%) and percentages (%) of cells at each stage. ( E , G ) Flow cytometry analysis of cell apoptosis and cell cycle. ( H ) CCK8 assay of BPH-1 cells. *** means p < 0.001 between si-con and si-2, ### means p < 0.001 between si-2 and si-2+rHuCXCL13. ( I , J ) Western blot assay of cell-cycle-, cell-apoptosis- and pathway-related proteins. ( K ) Relative densitometric quantification of cell-cycle-, cell-apoptosis- and pathway-related proteins. ( L ) Western blot assay of EMT-related proteins. ( M ) Relative densitometric quantification of EMT-related proteins. * p < 0.05, ** p < 0.01, *** p < 0.001 and ns means no significant difference.

Article Snippet: Human benign prostatic enlargement epithelia cell line BPH-1 (Cat. BNCC339850) was purchased from the Procell Co., Ltd. in Wuhan, China.

Techniques: Knockdown, Flow Cytometry, CCK-8 Assay, Western Blot

Journal: International Journal of Molecular Sciences

Article Title: Changes in the Expression and Functional Activities of C-X-C Motif Chemokine Ligand 13 ( CXCL13 ) in Hyperplastic Prostate

doi: 10.3390/ijms24010056

Figure Lengend Snippet: Anti-CXCR5 (1 μg/mL) could rescue the alternations induced by rHuCXCL13 in BPH-1 cells. ( A , B ) Flow cytometry analysis of cell cycle and cell apoptosis. ( C , D ) Statistical analysis of percentages (%) of cells at each stage and apoptotic rate (%). ( E ) CCK8 assay. ( F – H ) Western blot assay of cell-cycle-, apoptosis-, EMT- and pathway-related proteins. ( I ) Relative densitometric quantification of cell-cycle-, apoptosis-, EMT- and pathway-related proteins. * p < 0.05, ** p < 0.01, *** p < 0.001 and ns means no significant difference.

Article Snippet: Human benign prostatic enlargement epithelia cell line BPH-1 (Cat. BNCC339850) was purchased from the Procell Co., Ltd. in Wuhan, China.

Techniques: Flow Cytometry, CCK-8 Assay, Western Blot